C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.

<h4>Background and aim</h4>Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors...

Full description

Bibliographic Details
Main Authors: Tsuguru Hayashi, Michihiko Shibata, Shinji Oe, Koichiro Miyagawa, Yuichi Honma, Masaru Harada
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0244370